---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-030955"
form_type: "8-K"
ticker: "TLPH"
cik: "0001427925"
company_name: "TALPHERA, INC."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:05:38.185463+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AcelRx Q3 net loss $1.4M; Niyad gets FDA IDE approval, registrational study to start Q4

## Summary
- Net loss from continuing ops $1.4M ($0.08/sh); revenue $0.1M from DSUVIA royalty.
- Cash $13.4M at Sep 30; Oxford senior debt fully repaid in Q2 2023.
- FDA IDE approval for Niyad (regional anticoagulant for dialysis); NEPHRO study to start Q4, data mid-2024.
- July private placement raised $10M, with potential $16.3M additional upon milestone warrants.
- Combined R&D and SG&A expenses $3.4M, down from $4.5M YoY; headcount reduction offset by Niyad costs.

## SEC filing metadata
- accession: 0001437749-23-030955
- form_type: 8-K
- ticker: TLPH
- cik: 0001427925
- company_name: TALPHERA, INC.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427925/000143774923030955/0001437749-23-030955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427925/000143774923030955/acrx20231107_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-030955
- JSON: https://secwatch.observer/filing/0001437749-23-030955.json
- Plain text: https://secwatch.observer/filing/0001437749-23-030955.txt

## Key facts
- Earnings Releases
  TALPHERA, INC. reported the three months ended September 30, 2023 results: revenue $0.1 million, net income $1.4 million, EPS $0.08 per basic and diluted share.
  - Period: the three months ended September 30, 2023
  - Revenue: $0.1 million
  - Net income: $1.4 million
  - EPS: $0.08 per basic and diluted share
  - Result: reported results
  source text: ● The cash and cash equivalents balance was $13.4 million as of September 30, 2023. The senior debt with Oxford was fully repaid in the second quarter of 2023. ● Revenues of $0.1 million for the third quarter primarily represent the royalty revenue earned on the sales of DSUVIA by Alora, principally driven by sales to the Department of Defense. Revenues in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427925/000143774923030955/0001437749-23-030955-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.